Trial intelligence / Profile preview

Phase II study of UK-432,097 dry powder inhalation in moderate to severe COPD

2006-002578-23Phase 2Completed

Sponsor
Pfizer
Start
Sep 2006
Modality
Small Molecules
Countries
1
01

Overview

Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing UK-432,097 DPI with Placebo DPI (2 arms). Primary endpoint: Change from baseline in trough FEV1 at Week 6. Started Sep 2006; status: completed.

02

Drugs

UK-432097
03

Conditions

chronic obstructive pulmonary disease (COPD)

Beyond the preview

Go deeper on 2006-002578-23.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2006-002578-23.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call